Flamel Technologies S.A. (NASDAQ:AVDL) Director Craig R. Stapleton bought 20,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were bought at an average price of $9.52 per share, for a total transaction of $190,400.00. Following the completion of the acquisition, the director now owns 507,678 shares of the company’s stock, valued at $4,833,094.56. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Flamel Technologies S.A. (NASDAQ AVDL) traded up 0.22% during trading on Thursday, reaching $9.22. The company’s stock had a trading volume of 127,033 shares. The company’s 50 day moving average price is $9.04 and its 200 day moving average price is $9.83. The company has a market cap of $369.57 million, a P/E ratio of 9.74 and a beta of 1.39. Flamel Technologies S.A. has a 52 week low of $8.14 and a 52 week high of $14.15.

Flamel Technologies (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.05 by $0.14. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.84%. The firm had revenue of $46.30 million for the quarter, compared to analysts’ expectations of $45.17 million. Flamel Technologies’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, equities analysts anticipate that Flamel Technologies S.A. will post $1.16 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Flamel Technologies S.A. (AVDL) Director Purchases $190,400.00 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/14/flamel-technologies-s-a-avdl-director-purchases-190400-00-in-stock.html.

Large investors have recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its position in Flamel Technologies by 2,484.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock worth $121,000 after buying an additional 10,532 shares in the last quarter. US Bancorp DE bought a new stake in Flamel Technologies during the 1st quarter worth about $121,000. Sei Investments Co. lifted its position in Flamel Technologies by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after buying an additional 2,900 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Flamel Technologies during the 2nd quarter worth about $181,000. Finally, State of Tennessee Treasury Department bought a new stake in Flamel Technologies during the 2nd quarter worth about $194,000. 69.09% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have weighed in on AVDL. Roth Capital set a $15.00 target price on Flamel Technologies and gave the company a “buy” rating in a report on Wednesday, August 9th. Langenberg & Company restated a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Flamel Technologies in a report on Thursday, September 7th. Ladenburg Thalmann Financial Services raised their target price on Flamel Technologies from $27.00 to $30.00 in a report on Thursday, September 7th. Finally, Zacks Investment Research upgraded Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Monday, July 17th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $19.83.

Flamel Technologies Company Profile

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Insider Buying and Selling by Quarter for Flamel Technologies (NASDAQ:AVDL)

Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.